-
Finance and Audit Committee
We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Enzon Pharmaceuticals Inc.'s financial performance into perspective.
Finance and Audit Committee
Finance and Audit Committee
Robert Salisbury (Chairman)
Robert LeBuhn
Phillip M. Renfro
Rolf A. Classon
Charter
Search
| (ENZN) NASDAQ | |||
| Last Trade | 9.85 | ||
| Change(%) |  | +0.04 | |
| Volume | 652143 | ||
| 2:00 AM - Mar 10, 2010 | |||
News
-
09-10-2009
Enzon to Present at NewsMakers...
Enzon to Present at NewsMakers in the Biotech Industry Conference
-
07-27-2009
Enzon to Release Second Quarte...
Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow
-
07-27-2009
Enzon to Present at BMO Focus...
Enzon to Present at BMO Focus on Healthcare Conference
-
07-23-2009
Enzon Enhances Governance with...
Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director
-
06-01-2009
Enzon Presents Clinical Data f...
Enzon Presents Clinical Data from HIF-1 Alpha Antagonist Study at ASCO
-- First specific HIF-1a inhibitor is well tolerated with early signs of clinical benefit-- -
11-29-2007
Enzon to Present at BMO Capita...
Enzon to Present at BMO Capital Markets Focus on Healthcare Conference
-
02-10-2009
Enzon Discontinues Further Dev...
Enzon Discontinues Further Development of rhMBL
-
05-21-2009
Enzon Stockholders Approve Com...
Enzon Stockholders Approve Company Proposals at 2009 Annual Meeting
-
07-27-2009
Enzon to Present at BMO Focus...
Enzon to Present at BMO Focus on Healthcare Conference
-
05-06-2009
Enzon Reaches Phase II Dose fo...
Enzon Reaches Phase II Dose for PEG-SN38
-- Composition of matter patent granted until 2027-- -
09-30-2008
Enzon's New Oncaspar-IV™ Rec...
Enzon's New Oncaspar-IV™ Receives Orphan Drug Status in the EU
-- Improved version to expand global potential -- -
10-30-2007
Enzon Initiates Second Phase 1...
Enzon Initiates Second Phase 1 Study of Its HIF-1 Alpha Antagonist